Review Article
Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
Table 3
Selected studies of pretransplantation PET in relapsed/refractory Hodgkin’s lymphoma.
| | Study | Prospective | Type of FI | No. | No. FI+ (%) | PPV | NPV | EFS, FI+ | EFS, FI– | Median follow-up |
| | Spaepen et al. 2003 [81] | no | PET | 19 | 9 (47%) | 78% | 90% | — | — | — |
| | Schot et al. 2007 [82] | yes | PET | 23 | 5 (22%) NMR, 10 (43%) PMR | 60% if NMR, 70% if PMR | 75% if CMR, 30% if PMR | 40% (2 y) if NMR, 37% if PMR | 73% (2 y) if CMR | — |
| | Jabbour et al. 2007 [83] | no | 67Ga or PET | 211 | 57 (27%) | 74% | 68% | 23% (3 y) | 69% (3 y) | 34 mo for nonrelapsed pts | | | PET | 68 | 25 (37%) | 72% | 77% | — | — | — |
| | Castagna et al. 2009 [84] | no | PET, after 2 cycles | 24 | 10 (42%) | 90% | 93% | 10% (2 y) | 93% (2 y) | 24 mo | | | PET, after 4 cycles | 24 | 6 (25%) | — | — | 0% (2 y) | 78% (2 y) | 24 mo |
| | Moskowitz et al. 2010 [45] | yes | 67Ga or PET | 105 | 41 (39%) | — | — | 33% (4 y) | 77% (4 y) | 7 y in surviving pts |
|
|
CMR: complete metabolic remission; EFS: event-free survival; FI: functional imaging; Ga: Gallium; NMR: no metabolic remission; NPV: negative predictive value; PMR: partial metabolic remission (residual intensity above background level); PPV: positive predictive value; pts, patients.
|
